Dupixent Dangers Drive Growing Cancer Lawsuits

We are investigating a growing number of lawsuits involving Dupixent (dupilumab), a widely used drug prescribed for eczema, asthma, and other allergic conditions. As more patients come forward, these cases are raising concerns about a possible link between Dupixent and a rare cancer called cutaneous T-cell lymphoma (CTCL).

One recent lawsuit filed in federal court involves a Georgia woman who claims Dupixent caused or worsened her cancer. According to the complaint, she began using the drug in 2019 to treat eczema. About a year later, she was diagnosed with mycosis fungoides, a common form of CTCL, and now requires ongoing cancer treatment.

What the Lawsuits Claim

Across the country, patients are filing claims against Dupixent’s manufacturers, Regeneron Pharmaceuticals and Sanofi. These lawsuits allege the companies:

• Failed to warn patients and doctors about a possible cancer risk
• Did not update safety labels as new information became available
• Allowed continued use of the drug without fully disclosing known risks

Some patients claim they developed CTCL after taking Dupixent, while others say the drug caused their condition to worsen or progress more quickly.

Medical Concerns Continue to Grow

Researchers are continuing to study the possible connection between Dupixent and lymphoma. Some studies and case reports have described patients who developed or experienced worsening CTCL after starting the drug.

At the same time, federal regulators are reviewing safety data. The FDA has identified CTCL as a potential safety signal and is evaluating whether stronger warnings may be needed.

What Is Cutaneous T-Cell Lymphoma?

Cutaneous T-cell lymphoma is a rare cancer that begins in white blood cells and appears on the skin. It can look like common conditions such as eczema, which can delay diagnosis.

Symptoms may include:

• Red or scaly patches
• Persistent itching
• Thickened skin or bumps
• Skin that does not respond to treatment

Because early symptoms often resemble less serious conditions, CTCL can be difficult to recognize right away.

Talk to Beasley Allen About Your Case

Beasley Allen attorneys Ryan Duplechin and Cade Crow are representing individuals who took Dupixent and later developed CTCL or related cancers.

If you or a loved one used Dupixent and were later diagnosed with cutaneous T-cell lymphoma, you may have a claim. Our team can review your case at no cost and help you understand your legal options.